Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Evogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 19/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.67 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evogliptin SCHEMBL2491978 | 1.00 | DPP4 (0.98) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2496606 | 1.00 | DPP4 (0.98) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL343846 | 0.99 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL343847 | 0.99 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL30866226 | 0.99 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL18331680 | 0.99 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2298513 | 0.99 | DPP4 (1.00) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2493817 | 0.97 | DPP4 (0.96) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2493812 | 0.97 | DPP4 (0.96) | DPP4KCNH2DPP8DPP7 | |
| Evogliptin SCHEMBL2493525 | 0.96 | DPP4 (0.93) | DPP4KCNH2DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142519-B1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | DONG A PHARM CO LTD (KR) | 2014-09-24 | — | — | EP | claimed |
| US-8030315-B2 | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity | DONG-A PHARM. CO., LTD. (KR) | 2011-10-04 | — | — | US | claimed |
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DONG-A PHARM. CO., LTD (KR) | 2010-05-13 | — | — | US | claimed |
| EP-2142519-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | Dong-A Pharm.Co., Ltd. (KR) | 2010-01-13 | — | — | EP | claimed |
| WO-2008130151-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | DONG-A PHARM. CO., LTD. (KR) | 2008-10-30 | — | — | WO | claimed |
| EP-2142519-B1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | DONG A PHARM CO LTD (KR) | 2014-09-24 | — | — | EP | disclosed |
| US-8030315-B2 | DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating diabetes or obesity | DONG-A PHARM. CO., LTD. (KR) | 2011-10-04 | — | — | US | disclosed |
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DONG-A PHARM. CO., LTD (KR) | 2010-05-13 | — | — | US | disclosed |
| EP-2142519-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | Dong-A Pharm.Co., Ltd. (KR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008130151-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING A DIABETES OR AN OBESITY | DONG-A PHARM. CO., LTD. (KR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120790-A1 | DPP-IV INHIBITOR INCLUDING BETA-AMINO GROUP, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR PREVENTING AND TREATING DIABETES OR OBESITY | DPP4, DPP7, DPP3 | DPP4 1/4885KCNH2 1962/4885DPP8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.